
PreludeDx Appoints Dr. Leona Hamrick as Senior Director, Medical Affairs



Hamrick to Further Expand Integration of DCISionRT into Clinical Practice for DCIS Breast Cancer Patients

Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer announced the appointment of Dr. Leona Hamrick DHSc, PA-C, MSL-BC to the newly created position of Senior Director, Medical Affairs. This role is a strategic addition to the leadership team as PreludeDx accelerates adoption, educations and advocacy of its ductal carcinoma in situ (DCIS) risk assessment test, DCISionRT.

"We have generated and published extensive and robust clinical evidence for DCISionRT and are now poised to expand accessibility to additional patients and physicians worldwide," said Dan Forche, President and CEO of PreludeDx. "With her deep experience in precision medicine, medical expertise and strong relationships with key stakeholders in the field of oncology, I am pleased to welcome Dr. Hamrick to PreludeDx's leadership team. In this newly created role, she will play a critical function assisting physicians with the incorporation of DCISionRT into their practices."

Dr. Hamrick brings nearly three decades of experience in the medical field, first as a healthcare provider and adjunct professor and then as a patient advocate and medical affairs liaison. She joins PreludeDx from Biodesix where she served as the VP, Clinical Development & Medical Affairs and was responsible for worldwide medical affairs strategy and execution. Prior to Biodesix, she served in other relevant roles at Veracyte and Lumicell. Additionally, Dr. Hamrick served as an advanced healthcare provider for many years. She obtained her Doctor of Health Science degree from Nova Southeastern University in Fort Lauderdale, Florida. She also holds a Master of Science in Physician Associate (PA) Studies from University of Nebraska Medical Center, as well as a Bachelor of Science in PA Studies from Mountain State University.

"I'm inspired by PreludeDx's commitment to advancing precision medicine for early-stage breast cancer patients and their physicians," said Hamrick. "As a breast cancer survivor, my passion is to advocate for breast cancer patients and drive better outcomes and quality of life. I am excited to join PreludeDx at such an important time, and to work closely with physicians to incorporate DCISionRT into their practices, enabling the power of precision medicine for individualized patient decision making and improved outcomes."

Source: [PreludeDx](#)

Published on : Thu, 3 Aug 2023